We explore the immense potential of gamma delta T cells, and the challenges in sourcing and scaling up sufficient volumes to ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

At the Outsourcing in Clinical Trials Conference in New England, experts shared insights on how the US clinical trial and ...

RAPT Therapeutics’ CEO Brian Wong said there was no “viable path forward” for the compound. Image credit: Shutterstock/Andrii Yalanskyi. RAPT Therapeutics has called it quits on a clinical programme ...

Paratek’s Nuzyra is approved by the US Food and Drug Administration (FDA) as a treatment for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections ...

Also known as a polymyxin B haemoperfusion (PMX), Toraymyxin is a haemoperfusion device that removes endotoxin, a toxic ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Radella Pharmaceuticals has reported topline outcomes from a Phase Ia trial that assessed an investigational therapy for ...

Lord Vallance stated the government sees investment, innovation, and public-private partnership as crucial to UK healthcare.

Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM' pipeline disease-modifying therapies for ...

Minghui Pharmaceutical has reported promising initial outcomes from its Phase I trial of MHB039A to treat patients with solid ...

Ionis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.